Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metabolically armed anti-CD19 chimeric antigen receptor T cell therapy - Leman Biotech

Next Previous
Drug Profile

Metabolically armed anti-CD19 chimeric antigen receptor T cell therapy - Leman Biotech

Alternative Names: Anti-CD19 chimeric antigen receptor T cell therapy - Leman Biotech; Meta10-19 - Leman Biotech

Latest Information Update: 15 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Leman Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Systemic lupus erythematosus
  • Phase 0 Non-Hodgkin's lymphoma
  • No development reported Diffuse large B cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 08 Jul 2026 Leman Biotech in collaboration with Institute of Hematology & Blood Diseases Hospital, China plans a phase 0 trial for Autoimmune haemolytic anaemia (Treatment-experienced) in China (IV, infusion) (NCT07689604)
  • 02 Jun 2026 Efficacy and adverse events data from a phase I trial in Diffuse large B cell lymphoma were presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 28 Mar 2026 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Late-stage disease, Recurrent, Second-line therapy or greater) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top